Wednesday, October 13, 2021 Daily Archives

Big Solutions Come in Small Packages: Expanding Sterile Connection Technology to Small-Format Product or Process Fluid Volume Transfer Applications

by

This webcast features: Troy Ostreng, Senior Product Manager, Colder Products Company In state-of-the-art biopharmaceutical manufacturing, you’re challenged to engineer and operate processes that are robust, reliable and repeatable. Building on the inventiveness of CPC and its AseptiQuik® Series Connectors, the leader in single-use connection technology, the company’s new MicroCNX™ Series Connectors provide a modern alternative to the tube welding process. In this presentation, CPC’s biopharma senior product manager, Troy Ostreng highlights how this new category of aseptic, sterile micro-connectors provides…

October 13, 2021

The Importance of Raw Materials in Viral Vector Manufacturing

by

Focus on transfection reagent. The rapid advance of so many gene therapy candidates is creating several key challenges. There is a strong need for higher viral vector yields and scalable manufacturing to reduce costs of gene therapy for affordable patient treatment, all of that while meeting cGMP compliance to ensure patient safety which, push comes to shoves, always comes first. A critical step for viral vector manufacturing is sourcing of raw materials to maximize production yield while meeting quality requirement.…

October 13, 2021

CureVac manufacturing switch-up as it shelves COVID-19 vax

by

CureVac will shift its manufacturing setup to produce clinical material for second-generation mRNA vaccine candidates as it abandons CVnCoV.   Just one month ago, CureVac dropped two contract development manufacturing organization’s (CDMOs) after demand for mRNA COVID-19 candidate CVnCoV diminished but the firm remained confident future clinical trials would still go ahead.   Now, CureVac has decided to withdraw the first-generation vaccine candidate from the approval process with the European Medicines Agency (EMA) in a bid to “refocus efforts on improved second-generation vaccine candidates we are developing in collaboration with GSK.†According to the firm, its second-generation candidates are based on an improved mRNA setup and includes flu…

October 13, 2021

Aceto buffers up presence in bioprocessing with A&C buy

by

A&C Bio Buffer is the sixth acquisition for Aceto in the past two years and signals the firm’s ambitions in the biomanufacturing services space. The deal, financials of which have not been disclosed, brings Aceto a GMP (Good Manufacturing Practices) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products, with a facility in Limerick, Ireland producing over 50 products including biological buffers, process solutions, cleaning solutions and WFI (Water for Injection). “A&C Bio…

October 13, 2021

Ins and outs: High level changes at BlueRock, Pfizer and the NIH

by

Emile Nuwaysir has stepped down from his position as CEO of BlueRock and moves to in vivo cell therapy firm Ensoma. Meanwhile, there are changes at Pfizer and the National Institutes of Health (NIH). Nuwaysir has been CEO of Bayer’s subsidiary BlueRock Therapeutics since 2017. Since then, the company has transitioned from a preclinical start-up to a clinical-stage firm that employs over 200 people across two countries. Nuwaysir will remain at the company as a board chair and continue to…

October 13, 2021

Lonza ups mammalian cell services in Singapore

by

The increased capabilities in Singapore will support both upstream and downstream processing and analytical development, the CDMO says. The size of the investment has not been disclosed, but Jeetendra Vaghjiani, senior director of Clinical Development for Mammalian Biologics, Lonza told this publication the expansion consists of a 1800 m2 lab built at the Singapore Science Park in Tuas along with the renovation of an existing 1500 m2 lab. “We are adding more capacity across all our technologies, supporting upstream and…

October 13, 2021